<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7148454\results\search\drugs\results.xml">
  <result pre="been demonstrated in immunocompetent mouse models in the presence of" exact="cyclosporine" post="A or anti-CD4/anti-SD8 antibodies as immunosuppressant agents [144]. This"/>
  <result pre="from phase Ib reported the combination therapy of CAV21 with" exact="ipilimumab" post="in patients with advanced melanoma [151]. A cohort of"/>
  <result pre="3, 5, 8 and 22, followed by six injections of" exact="ipilimumab" post="(3 mg/kg), beginning on day 22. The ORR was"/>
  <result pre="for metastatic uveal melanomaCancer Immunol. Immunother.2019681179118510.1007/s00262-019-02352-631175402 9.HodiF.S.Oâ€™DayS.J.McDermottD.F.WeberR.W.SosmanJ.A.HaanenJ.B.GonzalezR.RobertC.SchadendorfD.HasselJ.C.et al.Improved survival with" exact="ipilimumab" post="in patients with metastatic melanomaN. Engl. J. Med.201036371172310.1056/NEJMoa100346620525992 10.HauschildA.GrobJ.-J.DemidovL.V.JouaryT.GutzmerR.MillwardM.RutkowskiP.BlankC.U.MillerW.H.KaempgenE.et"/>
  <result pre="phase 3 randomised controlled trialLancet201238035836510.1016/S0140-6736(12)60868-X22735384 11.McArthurG.A.ChapmanP.B.RobertC.LarkinJ.HaanenJ.B.DummerR.RibasA.HoggD.HamidO.AsciertoP.A.et al.Safety and efficacy of" exact="vemurafenib" post="in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up"/>
  <result pre="studyLancet Oncol.20141532333210.1016/S1470-2045(14)70012-924508103 12.RobertC.KaraszewskaB.SchachterJ.RutkowskiP.MackiewiczA.StroiakovskiD.LichinitserM.DummerR.GrangeF.MortierL.et al.Improved overall survival in melanoma with combined" exact="dabrafenib" post="and trametinibN. Engl. J. Med.2015372303910.1056/NEJMoa141269025399551 13.LongG.V.StroyakovskiyD.GogasH.LevchenkoE.De BraudF.LarkinJ.GarbeC.JouaryT.HauschildA.GrobJ.-J.et al.Dabrafenib and"/>
  <result pre="dabrafenib and trametinibN. Engl. J. Med.2015372303910.1056/NEJMoa141269025399551 13.LongG.V.StroyakovskiyD.GogasH.LevchenkoE.De BraudF.LarkinJ.GarbeC.JouaryT.HauschildA.GrobJ.-J.et al.Dabrafenib and" exact="trametinib" post="versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A"/>
  <result pre="trametinibN. Engl. J. Med.2015372303910.1056/NEJMoa141269025399551 13.LongG.V.StroyakovskiyD.GogasH.LevchenkoE.De BraudF.LarkinJ.GarbeC.JouaryT.HauschildA.GrobJ.-J.et al.Dabrafenib and trametinib versus" exact="dabrafenib" post="and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind,"/>
  <result pre="nude miceCurr. Gene Ther.201212677610.2174/15665231280009959922384806 39.JhaB.K.DongB.NguyenC.T.PolyakovaI.SilvermanR.H.Suppression of antiviral innate immunity by" exact="sunitinib" post="enhances oncolytic virotherapyMol. Ther.2013211749175710.1038/mt.2013.11223732991 40.ShapiraS.ShapiraA.KazanovD.HevroniG.KrausS.ArberN.Selective eradication of cancer cells"/>
  <result pre="Treat.2009113213010.1007/s10549-008-9899-218256929 98.SkeldingK.A.BarryR.D.ShafrenD.R.Enhanced oncolysis mediated by Coxsackievirus A21 in combination with" exact="doxorubicin" post="hydrochlorideInvestig. New Drugs20123056858110.1007/s10637-010-9614-021170760 99.BerryL.J.AuG.G.BarryR.D.ShafrenD.R.Potent oncolytic activity of human enteroviruses"/>
  <result pre="clinical trialAnn. Surg Oncol.2016234169417710.1245/s10434-016-5286-027342831 118.PuzanovI.MilhemM.M.MinorD.HamidO.LiA.ChenL.ChastainM.GorskiK.S.AndersonA.ChouJ.et al.Talimogene laherparepvec in combination with" exact="ipilimumab" post="in previously untreated, unresectable stage IIIB-IV melanomaJ. Clin. Oncol.201610.1200/JCO.2016.67.1529"/>
  <result pre="a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic" exact="ipilimumab" post="in advanced melanoma patients previously treated with anti-PD1 blockade"/>
 </snippets>
</snippetsTree>
